Application Guidelines for the Crazy 8 Initiative Award Program

Letter of Intent Due: October 1, 2019

Full Application Due: January 21, 2020

Finalist Presentations: April 22-23, 2020
# Table of Contents

**About Alex’s Lemonade Stand Foundation (ALSF)** ........................................................................................................3

**The Crazy 8 Initiative Award Program** .........................................................................................................................3

<table>
<thead>
<tr>
<th>Background</th>
<th>........................................................................................................3</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Crazy 8 Commitment</td>
<td>........................................................................................................4</td>
</tr>
</tbody>
</table>

**Program Description** ..................................................................................................................................................4

- Application Timeline and Review .................................................................................................................................5
- Eligibility ..........................................................................................................................................................................5
- Budget ...........................................................................................................................................................................5

**Project Mission Relevance** ........................................................................................................................................6

- Developmental Origins of Pediatric Cancers ..................................................................................................................6
- Drugging Currently Undruggable Pediatric Cancer Drivers ..........................................................................................7
- Developing Novel Immunotherapies ...............................................................................................................................7
- Discovery and Development of Novel Pediatric Cancer Drug Targets ..........................................................................8

**Resource and Data Sharing** .......................................................................................................................................8

**Restrictions** ..................................................................................................................................................................9

**Grant Reporting Requirements** ..................................................................................................................................9

**Letter of Intent Instructions** .........................................................................................................................................9

**Full Proposal Instructions** ........................................................................................................................................10

- Application Package .....................................................................................................................................................10
  - Format Instructions ..................................................................................................................................................10
  - Section Descriptions ..............................................................................................................................................10

**Application Submission Instructions** ..........................................................................................................................12

**Contact** ......................................................................................................................................................................13
About Alex’s Lemonade Stand Foundation (ALSF)

Alex’s Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. Her spirit and determination inspired others to support her cause, and when she passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a national fundraising movement. Today, ALSF is one of the leading funders of pediatric cancer research in the U.S. and Canada, funding nearly 1,000 research projects and providing programs to families affected by childhood cancer. ALSF is also the only childhood cancer research organization that has been given the NCI peer-reviewed funder designation for rigorous selection of research grants. The mission of ALSF is to improve the lives of children with cancer by funding impactful research, raising awareness, and supporting families with the ultimate goal of curing all children with cancer.

The Crazy 8 Initiative Award Program

Background

Alex’s Lemonade Stand Foundation (ALSF) has focused on enhancing collaborations that develop cures since its beginning. As ALSF continues to distinguish itself as a leader in funding childhood cancer research and accelerating cures, the Foundation’s grants have facilitated unprecedented collaborations between the brightest minds in childhood cancer research from around the globe. ALSF launched the Crazy 8 Initiative with the purpose of harnessing that collaborative spirit to detail roadmaps to cures for specific high-risk childhood cancers and to identify and solve critical challenges facing the childhood cancer community.

The Crazy 8 Initiative kicked off in 2018 with a meeting that brought together more than 90 top scientists from around the world to contribute their expertise in eight key pediatric oncology disciplines.

Crazy 8 Disciplines

1. Embryonal brain cancers
2. High grade gliomas
3. Fusion positive sarcomas
4. Fusion negative sarcomas
5. Leukemias
6. Neuroblastoma
7. Big data
8. Catalyzing clinical trials

The group aimed to undertake the big question: How can we tackle major obstacles impeding progress towards cures for childhood cancer through multidisciplinary collaborative research? The outcomes of the meeting included a list of addressable problems and proposed pathways forward to overcome these obstacles to make cures a reality. The group identified four cross-cutting research themes that form the basis of this RFA, with the overarching goal of making a major impact on the field of childhood cancer.

Crazy 8 Research Themes

1. Developmental Origins of Pediatric Cancers
2. Drugging Currently Undruggable Pediatric Cancer Drivers
3. Developing Novel Immunotherapies
4. Discovery and Development of Novel Pediatric Cancer Drug Targets

The Crazy 8 Commitment

In addition to its current grant opportunities, the Crazy 8 Initiative creates a new funding pillar for ALSF, allowing the foundation to tackle specific challenges in pediatric cancer research that require substantial support for collaborative teams. ALSF has committed $25 million to support the Crazy 8 Initiative.

Program Description

The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of new cure discovery. The proposal should address a topic that is responsive to at least one of the four pediatric cancer research themes listed above. It is expected that successful applications will address one or more of the eight disciplines that formed the basis of the Crazy 8 initiative.

Investigations may involve the exploration of a novel scientific hypothesis or the development of new model systems, tools or technologies that have the potential for significant impact on the field of childhood cancer. Collaboration and data sharing are a priority for this research program. We expect successful applications to propose multidisciplinary teams with a very clear plan for collaboration that would empower the study of big ideas that would not be easily addressable otherwise. Childhood cancer research applicants are encouraged to bring new, necessary
expertise into the field. The awards will be judged on scientific soundness, significance and the potential for impact on improving the lives of children with cancer.

Application Timeline and Review

- A letter of intent (LOI) must be submitted and all eligibility criteria met to be considered for the full proposal stage. The main purpose of the LOI is to determine the number of applications expected to be received.
- LOIs will be reviewed administratively, and full proposals will be reviewed by an independent panel of experts according to the NIH recognized peer-review process overseen by the Crazy 8 Initiative Scientific Advisory Board.

### CRAZY 8 INITIATIVE AWARD APPLICATION TIMELINE

<table>
<thead>
<tr>
<th>Event</th>
<th>Date/Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>LETTER OF INTENT DUE</td>
<td>October 1, 2019 by 11:59PM ET</td>
</tr>
<tr>
<td>INVITATION TO SUBMIT FULL PROPOSAL</td>
<td>November 2019</td>
</tr>
<tr>
<td>FULL PROPOSALS DUE</td>
<td>January 21, 2020 by 11:59PM ET</td>
</tr>
<tr>
<td>INVITATION TO PRESENT IN PERSON</td>
<td>March 2020</td>
</tr>
<tr>
<td>FINALIST PRESENTATIONS</td>
<td>April 22-23, 2020</td>
</tr>
<tr>
<td>GRANT START DATE</td>
<td>By July 1, 2020</td>
</tr>
</tbody>
</table>

**Eligibility**

- Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution.
- Applicants must have a track record of publication and funding productivity that should demonstrate that the project can be accomplished by the investigators.
- Applicant institutions may be based in the United States or abroad, and applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.

**Budget**

The requested budget should be in proportion to the scope of the proposed project and its corresponding potential for impact. Depending on the type of project and the size of the team, the requested budget should be in the range of $1-5 million USD over 4 years. Cost efficiency will be one of the major considerations in review and funding decisions. Funding is contingent upon satisfactory progress as determined by a Crazy 8 Initiative Scientific Advisory Board.

ALSF will pay up to 10% in indirect costs; if the applicant elects to request indirect costs, the budget may not exceed the range of $1-5 million USD. The 10% indirect costs should be assessed on the Total Direct Costs. Indirect costs may be assessed on subawards’ Total Direct Costs.
Costs, but must be excluded from the primary institution’s Total Direct Costs for calculating indirects.

In addition to the full requested budget, applicants may elect to use the ALSF Childhood Cancer Data Lab (CCDL) for single-cell and/or bulk gene expression analysis. The CCDL is also available for consultations regarding the management and sharing of your research data which is a required element of this award (see Resource & Data Sharing). The use of the CCDL is not required and is meant to serve as a benefit to investigators. For applicants interested in using the CCDL for gene expression analysis, please reach out to the CCDL Director, Casey Greene, PhD, at greenescientist@gmail.com to discuss the research plan in more detail. If interested, include the request as a line item on the ALSF budget template.

Project Mission Relevance

The aims of the research proposals must be designed to directly address the most intractable issues in pediatric cancer research today with the ultimate goal of curing pediatric malignancies. The proposal should be responsive to at least one of the four research themes listed above and described in more detail below, with priority given to projects addressing one or more of the Crazy 8 disciplines.

**Developmental Origins of Pediatric Cancers**

Childhood cancers show developmental specificity based on age and tumor location at diagnosis, which suggests that there are particular vulnerabilities as cells progress through developmental programs. Enhanced understanding of the cellular origins and usurped developmental pathways essential in childhood cancers is needed to address why certain cells are predisposed to tumorigenesis in distinct developmental contexts. Discerning how these cells go through malignant transformation may provide novel, druggable pathways. Areas of interest include, but are not limited to:

- Identifying cell of origin in childhood cancers
- Understanding how genetic alterations impart tumorigenesis during specific timepoints of development
- Discovering how epigenetic modifications influence cancer predisposition in a developmental context and how these modifications influence cancer progression
- Understanding the tissue-specific microenvironmental influence on pediatric cancer progression
- Identifying cell-specific vulnerabilities that may be targeted while minimizing harm to the normal development of tissues
- Using cell-of-origin identity to develop appropriate preclinical models
• Uncovering the effects of sex, race or ethnicity on cellular development and disease predisposition

Drugging Currently Undruggable Pediatric Cancer Drivers
Chromosomal translocations that lead to fusion oncoproteins, such as EWS-FLI in Ewing sarcoma and PAX3/7-FOXO1 in alveolar rhabdomyosarcoma, are commonly found in childhood cancers and are difficult to target. More broadly, oncoproteins critical to childhood cancers, such as transcription factors like MYCN, are notoriously challenging to target due to nuclear localization and the lack of an obvious binding pocket. More understanding of the biological mechanism and structural basis of these oncoproteins is needed as well as model systems in which to study them in order to identify potential therapeutic targets. Areas of interest include, but are not limited to:

• Understanding the underlying molecular mechanism of these difficult to drug oncoproteins
• Developing models (e.g. cell lines, iPSC models, animal models) that recapitulate the disease
• Small molecule and/or functional genomic screening for hits and subsequent validation
• Understanding the structural biology of the oncoprotein and the key protein members of the oncoprotein complex to discover unique vulnerabilities
• Identifying targetable proteins that have enhanced effects in the presence of an undruggable oncoprotein
• Developing novel therapies based on any of the areas above, including protein degraders and immunotherapies

Developing Novel Immunotherapies
Immunotherapies hold great promise in the treatment of childhood cancer, but there are challenges to their broad implementation including few known tumor-specific targets on the surface of cancer cells or presented on the MHC complex, the immunosuppressive tumor microenvironment, immune evasion and treatment resistance, and the need for better model systems for testing. Areas of interest include, but are not limited to:

• Characterizing the tumor microenvironment and its role in the response to therapy
• Identifying the molecules found on the surface of cancer cells and/or presented in the context of MHC to inform new target development
• Studying the mechanisms of immune system evasion
• Designing improved model systems to inform mechanistic understanding and preclinical testing of immunotherapies
• Developing novel immunotherapeutic approaches including multi-specific targeting and re-educating the adaptive immune response

Discovery and Development of Novel Pediatric Cancer Drug Targets
Childhood cancers exhibit a low mutational burden compared to adult cancers which makes finding targets challenging. Additionally, targets may evolve as cancers become resistant to standard therapies or relapse. The mechanisms of resistance and relapse in pediatric cancers are not well understood and a greater understanding of the underlying molecular evolution of the tumor and its microenvironment is needed. Areas of interest include, but are not limited to:

• Studying the molecular mechanisms of tumor resistance in response to therapy
• Understanding the biological processes that lead to metastasis
• Developing clinically relevant models to study resistance and relapse to prioritize drug discovery
• Characterizing tumor specimens before treatment, during, and upon relapse
• Using new technologies such as a single-cell RNA sequencing and single-nucleus sequencing to better understand tumor heterogeneity within and in the surrounding microenvironment
• Developing computational methods and workflows to analyze the large scale data
• Developing clinically relevant models for high-throughput and/or functional genomic screening
• Developing and validating new biomarkers
• Understanding cell-based dependencies and communication within the tumor microenvironment

Resource and Data Sharing
Applicants should consider how the research outputs produced under this award will enhance the pace of discovery across the field of pediatric cancer research. Reviewers will consider the extent to which the dissemination of resources produced under the award will enhance or diminish the impact of the proposed work. Applicants are required to describe their track record of generating resources that are broadly re-used, the specific resources that will be generated in the Crazy 8 project, and the mechanisms by which those resources will be shared. For a full description see the Resource Sharing Form.

Applicants are expected to share data generated by any research that receives ALSF funding. To demonstrate a commitment to sharing that will be actualized, applicants are encouraged to provide information in their application that clearly states the type of data that will be shared, the method, characterization and timing of such sharing, and the anticipated resources required.
by the applicant and the data user. This information should be captured in the Resource Sharing Plan. Patient consent information should be provided with the application and any limitations with regards to data use/sharing as per the consent should be highlighted.

Restrictions

- Grant proposals must be focused on pediatric translational oncology, from understanding basic biologic underpinnings to new therapies, in response to four Crazy 8 research themes.
- Funds may not be used for research utilizing human embryonic stem cells or non-human primates. Research with human induced pluripotent stem cells is permissible.

Grant Reporting Requirements

- Annual progress reports followed by an in-person meeting is required yearly.
- An interim 6-month progress update teleconference with ALSF is also required in addition to the annual written report and in-person meeting.
- Each year of funding is contingent upon demonstration of satisfactory progress toward the completion of proposed research objectives and appropriate budget expenditures.
- Minor carry-over of funds (25% or less) is permitted each year with justification. Each year’s budget will be approved subsequent to the review of project progress.
- A final report is required at the conclusion of funding. Report must state findings, expenditures, as well as publications and presentations which acknowledge ALSF funding. The grant may not be renewed; no cost extensions must be requested in the final report.
- Publications, presentations and posters featuring results of the experiments funded by this grant mechanism should acknowledge “Alex’s Lemonade Stand Foundation”. ALSF requests copies be sent via email to Grants@AlexsLemonade.org.

Letter of Intent Instructions

Letters of Intent are required for two reasons. First, ALSF staff will ensure that the proposed research is within the scope of the Crazy 8 initiative. Second, it will allow ALSF to constitute the appropriate scientific review committee in anticipation for the full applications.

- PI name, institution and project title must appear at the top of the page.
- No appendices allowed.
- Create a single PDF for all sections and biosketch(es) and upload to the ALSF online application form (see Application Submission Instructions).
The LOI must not exceed 2 pages and may not use a font smaller than 11-point. A reference section does not count toward the page limit. The following sections are required:

- **Broad Scientific Concept** – Please provide a narrative describing:
  a. The big problem and Crazy 8 theme that you will address
  b. The Crazy 8 disciplines that will be impacted
  c. The innovation you will propose to address the big problem
  d. Any unique attributes of your team
  e. Potential impact of your proposal on childhood cancer outcomes

- **Investigators and Institutions** – List all key personnel, disciplines and their affiliated institutions. It is understood that this may change and the list is not considered binding.

### Full Proposal Instructions

#### Application Package

- All sections described below should be combined into one PDF (max 20 MB) and uploaded to the ALSF online application form (see Application Submission Instructions).
- All templates mentioned can be found at ALSF’s Information for Grant Applicants page.

#### Format Instructions

- **PAGE HEADER:** All pages of the application should be numbered; the name of the principal investigator should appear in the upper right-hand corner of each page.
- **FORMAT:** Follow NIH format guidelines: Arial, Helvetica, Palatino Linotype, or Georgia fonts with a font size of 11 points or larger with a minimum of ½ inch margins.
- **ORDER & LENGTH:** The order of the application should be followed, adhering to the maximum number of pages allowed for each subsection indicated in parentheses.

#### Section Descriptions

1. **Project Information**
   a. **Cover Page (1 page):** Download and complete the Cover Page Template.
   b. **Table of Contents (1 page):** Provide a Table of Contents with page numbers to the corresponding sections.
   c. **Scientific Abstract (0.5 page):** Summarize the research objectives and rationale.
   d. **Impact Statement (0.5 page):** How will this project impact childhood cancer?

2. **Budget/Justification (3 pages):**
a. **Budget Template (1.5 pages):** Complete the [ALSF budget template](#). The signature from an institutional representative on the cover page of this grant application specifically acknowledges and accepts this budget.
   
i. The award amount is between $1-5 million over 4 years.
   
ii. ALSF adheres to the NIH salary cap for principal investigator(s).
   
iii. Indirect costs are allowed up to 10% and should be assessed on the Total Direct Costs.
   
iv. If utilizing a subaward, you must include their budget. Indirect costs may be assessed on subawards’ Total Direct Costs, but must be excluded from the primary institution’s Total Direct Costs for calculating indirects.
   
v. If using the [ALSF Childhood Cancer Data Lab](#) for single-cell and/or bulk gene expression analysis, include the request as a line item on the ALSF budget template.
   
v. Reasonable travel expenses to national/international research meetings to disseminate findings may be budgeted. Travel to the ALSF annual Crazy 8 meeting will be at no cost to the grant recipient.

b. **Budget Justification (1.5 pages)**

3. **Biographical Sketch(es):** Use the NIH five-page biographical sketch (SF424) format for the principal investigator and all key personnel.

4. **Research Plan**

a. **Specific Aims (1 page):** List the goals, long-term objectives and what the specific research proposed in this application is intended to accomplish. State the hypothesis to be tested and relevance to childhood cancer research.

b. **Research Strategy**

   i. **Significance (1-2 pages):** Describe the relevant background for the current research plan. State the significance and importance of your proposed project with respect to childhood cancer research. Relate the specific aims to the goals and long-term objectives.
   
   ii. **Innovation (0.5-1 page):** Describe how the proposed research challenges and shifts paradigms or introduces a novel concept, approach or technology.
   
   iii. **Approach (10 pages):** Describe the experimental approach to the research question and how the research will be realistically accomplished within the proposed funding period. This section should include *but is not limited to*:
      
      1. Timeline and deliverables
      2. Feasibility of the approach to reach project goals; if available, include PI’s preliminary studies pertinent to the project
3. Anticipated potential problems and plans to address these issues
   iv. Literature Cited: Use Vancouver or NIH style (numbered citations within text) format.

5. Human Subjects (0.5 page): If approved, include the IRB approval letter or equivalent. If approval is pending, indicate the expected approval date. Any funds awarded will be held until the letter is received. If IRB approval is not applicable, include a note in this section.

6. Vertebrate Animals (0.5 page): If approved, include the IACUC approval letter or equivalent. If approval is pending indicate the expected approval date. Any funds awarded will be held until the letter is received. If IACUC approval is not applicable, include a note in this section.

7. Letters of Support: Include any appropriate letters from individuals confirming their roles in the project. Institutional letters of support are not required, but can be included, especially if there are issues of feasibility that can be addressed.

8. Resource Sharing: Describe the outputs from the proposed project and how they will be shared. Reviewers will be asked to consider the manner in which resources will be shared and the extent to which this plan will increase or decrease the impact of the proposed project. Download and use the Resource Sharing Form to complete this section of the application.

9. Appendix: A brief appendix is allowed with the following limitations.
   a. Appendices should be included only if they are essential to the understanding of the application, including one accepted but not yet published manuscript or two pages of additional information such as a summary of the protocol if applicable and/or supplementary figures.
   b. Excessive appendices will result in the application being rejected administratively.

Application Submission Instructions

! Applicants must not use the IE browser as it is not compatible with the online portal. Chrome and Firefox browsers are recommended.

1. To start an application, navigate to the portal at ALSFapps.force.com.
   a. Returning applicants: login with your username and password.
   b. First time applicants: click the “New User?” link and complete your one-time registration and then login.

2. After you’ve logged in, follow the directions on the dashboard to submit your application. Complete the online form with applicant contact and project information.
   a. Enter the Project Title first, even if tentative. Then Save.
b. Applicant will be asked for basic contact information for themselves, co-PI(s) if applicable, grant manager and institution. If someone other than the PI is entering information into the portal, the “Contact Person” name entered must be the PI’s name.

c. In the respective sections enter the project title, budget request amount, type of childhood cancer the project focuses on, as well as a 250-word summary of the research project in lay terms (this will only be requested at the full application stage). The applicant will be asked to release this summary for use at ALSF’s discretion should the proposal be funded. The applicant may copy and paste information from other documents into these sections.

3. The application document must be uploaded as one PDF (maximum of 20 MB).

4. You may save your application to finish later. Go to ALSFapps.force.com and login again. You will land on your dashboard. Click “Applications” to edit your application in progress.

5. Once completed, submit the application by clicking Review & Submit. You will see error messages for any required fields that need to be completed.

6. After your application has been successfully submitted an email confirmation will be sent. You will not be able to amend the application after submission.

Contact

- If you have any questions regarding this grant mechanism, reach out to Anna Greene, Director of Science, at 866-333-1213 or by email at a.greene@alexslemonade.org.